24th January 2017
- 0 comments
24 January
BiVictriX Therapeutics (“BVX”) has today announced the completion of a successful fundraise to develop a new class of targeted cancer drugs. The company’s ‘Dual Targeting Approach’ is designed to give superior selectivity towards blood cancers. Acceleris Capital Ltd provided corporate finance advice to the Company.
...Register / Login now to read full story
In order to read the full story we need you to be registered with us, please click the links below to login or register.
Back to Homepage